Irinotecan |
| Catalog No.GC11473 |
Irinotecan is a topoisomerase inhibitor used primarily for the treatment of colorectal cancer. Irinotecan binds to the topoisomerase I-DNA complex, preventing DNA strand reconnection and leading to DNA double-strand breaks and cell death.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 97682-44-5
Sample solution is provided at 25 µL, 10mM.
Irinotecan is a topoisomerase inhibitor used primarily for the treatment of colorectal cancer. Irinotecan binds to the topoisomerase I-DNA complex, preventing DNA strand reconnection and leading to DNA double-strand breaks and cell death[1].
Irinotecan(2μM; 48h) treatment with Panc-1 and MIA PaCa-2 resulted in 57.5% reduction of migratory in Panc-1 cells and in a 53.9% in MIA PaCa-2 cells [1]. In the cell cycle analysis, Irinotecan (0.3 to 30μM for 24-48h ) increased the proportions at the S and G2/M phases of cell cycling in parallel with a decreased population at the G1 phase in Caco-2 and CW2 cells [2].
For xenografted HCT116 cells, Irinotecan (10mg/kg; i.p; 5days) can reduced tumors by 80% and mice urvival was again improved (>16weeks vs 12weeks in mock ） without any mouse toxicity[3]. Irinotecan (20mg/kg/day; ip; days 1–3, 8–10) were treat with Prostatic small cell carcinoma (SCC) arrested xenograft growth with a small reduction in tumor volume and only minor weight loss of the hosts (7%)[4]. Mice given a combination of Irinotecan (50mg/kg; ip; 1,13,19days ) had a decreased number of tumour cells in the peritoneal cavity as compared to non-treated mice but counts on macrophages, lymphocytes and neutrophils were higher than in non-treated mice[5].
[1]. Rodriguez Lanzi C, Wei R, Luo D, Mackenzie GG. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan. Neoplasia. 2022 Feb;24(2):133-144.
[2]. Kaku Y, Tsuchiya A, Kanno T, Nishizaki T. Irinotecan induces cell cycle arrest, but not apoptosis or necrosis, in Caco-2 and CW2 colorectal cancer cell lines. Pharmacology. 2015;95(3-4):154-9.
[3]. Sharma A, Vatapalli R, Abdelfatah E, Wyatt McMahon K, Kerner Z, A Guzzetta A, Singh J, Zahnow C, B Baylin S, Yerram S, Hu Y, Azad N, Ahuja N. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. PLoS One. 2017 Apr 26;12(4):e0176139.
[4]. Tung WL, Wang Y, Gout PW, Liu DM, Gleave M, Wang Y. Use of irinotecan for treatment of small cell carcinoma of the prostate. Prostate. 2011 May 15;71(7):675-81.
[5]. Sharma A, Vatapalli R, Abdelfatah E, Wyatt McMahon K, Kerner Z, A Guzzetta A, Singh J, Zahnow C, B Baylin S, Yerram S, Hu Y, Azad N, Ahuja N. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. PLoS One. 2017 Apr 26;12(4):e0176139.
| Cell experiment [1]: | |
Cell lines | LoVo and HT-29 cells |
Preparation Method | LoVo and HT-29 cells were exposed to different concentrations of irinotecan(0-80μg/ml; 24h ) to determine the IC50 values. |
Reaction Conditions | Irinotecan(0-80μg/ml; 24h ) |
Applications | The IC50 values of LoVo cells is 6μg/ml, and for HT-29 cells is 12μg/ml. |
| Animal experiment [2]: | |
Animal models | Ehrlich ascites tumour cells model |
Preparation Method | The mice were administered quercetin and naringin (100mg/kg ) daily for 3 consecutive days, beginning on day 3 after i.p. injection of Ehrlich ascites tumour cells. Irinotecan was administered i.p. at a dose of 50mg/kg on days 1, 13 and 19 . |
Dosage form | Irinotecan: 50mg/kg; ip; 1,13,19days |
Applications | Mice given a combination of irinotecan and flavonoids had a significantly decreased number of tumour cells in the peritoneal cavity as compared to non-treated mice but counts on macrophages, lymphocytes and neutrophils were significantly higher than in non-treated mice. |
References: | |
| Cas No. | 97682-44-5 | SDF | |
| Chemical Name | 4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate | ||
| Canonical SMILES | O=C(OC1)C(O)(CC)C2=C1C(N(CC3=C4N=C5C(C=C(OC(N6CCC(N7CCCCC7)CC6)=O)C=C5)=C3CC)C4=C2)=O | ||
| Formula | C33H38N4O6 | M.Wt | 586.68 |
| Solubility | >29.4mg/mL in DMSO | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7045 mL | 8.5225 mL | 17.0451 mL |
| 5 mM | 340.9 μL | 1.7045 mL | 3.409 mL |
| 10 mM | 170.5 μL | 852.3 μL | 1.7045 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *